Rui Avelar - Aug 14, 2023 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role: Chief Medical Officer and Head of Research & Development
Signature: /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Stock symbol: EOLS
Transactions as of: Aug 14, 2023
Transactions value $: -$22,707
Form type: 4
Date filed: 8/16/2023, 08:25 PM
Previous filing: Mar 16, 2023
Next filing: Feb 9, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EOLS	Common Stock	Award	$0	+19.7K	+5.86%	$0.00	356K	Aug 14, 2023	Direct	F1
transaction	EOLS	Common Stock	Sale	-$22.7K	-2.21K	-0.62%	$10.27	353K	Aug 16, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. On August 14, 2023, the Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of May 9, 2023. One-third of the PSU (6,557 shares) was vested and delivered immediately upon certification of the goal achievement. The remaining two-thirds will vest annually on the anniversary of May 9, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs.

Content

Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. On August 14, 2023, the Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of May 9, 2023. One-third of the PSU (6,557 shares) was vested and delivered immediately upon certification of the goal achievement. The remaining two-thirds will vest annually on the anniversary of May 9, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs.

Remarks:

Chief Medical Officer and Head of Research & Development